BIIB - Biogen partner Eisai begins FDA submissions for injectable Alzheimer's therapy
2024-05-15 07:44:07 ET
More on Biogen, Eisai Co., Ltd., etc.
- Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings
- Biogen: Don't Overthink This One
- Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
- Biogen says uptake for Alzheimer’s therapy is improving
- Biogen Non-GAAP EPS of $3.67 beats by $0.21, revenue of $2.29B misses by $30M